Welcome to our dedicated page for Cullinan Therapeutics SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cullinan Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cullinan Therapeutics's regulatory disclosures and financial reporting.
State Street Corporation reported beneficial ownership of common stock of Cullinan Therapeutics Inc. on a Schedule 13G. State Street beneficially owns 3,668,627 shares of common stock, representing 6% of the class. These shares are held with shared voting power over 3,565,748 shares and shared dispositive power over 3,668,627 shares, with no sole voting or dispositive power. The filing attributes the holdings to asset management subsidiaries including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.
Cullinan Therapeutics, Inc. reported a Q2 2026 net loss of $53.7 million, improving from $70.1 million a year earlier, driven by lower R&D and G&A spending. Research and development expenses were $44.4 million in the quarter and $86.6 million for the first half of 2026.
Cash, cash equivalents and short-term investments totaled $334.5 million as of June 30, 2026, with an additional $21.4 million in long-term investments and interest receivable, which management expects to fund operations for at least 12 months. The company continues to invest in its T cell engager pipeline, including CLN-978 for autoimmune diseases, velinotamig for autoantibody-driven disorders and CLN-049 for AML and MDS.
For zipalertinib, co-developed with Taiho, the U.S. FDA accepted a new drug application for previously treated EGFR exon 20 insertion NSCLC and set a February 27, 2027 action date, with additional Phase 3 data expected by year-end 2026. Cullinan also plans potentially registrational Phase 2 trials for CLN-049. The company notes it will become a large accelerated filer in 2027, which will increase compliance and reporting requirements.
Cullinan Therapeutics reported second‑quarter 2026 results and outlined multiple near‑term clinical catalysts. For CLN‑978 in SLE and RA, additional multi‑dose data are planned in Q4 and Q3 2026, with Phase 2 expansion studies targeted for early 2027, including lupus nephritis and difficult‑to‑treat RA.
Velinotamig showed early complete renal responses in two SLE nephritis patients in a China study, with more data expected Q4 2026 and a global Phase 1/2 basket trial in autoimmune cytopenias planned for early 2027. Following a positive End‑of‑Phase 1 FDA meeting, a potentially registrational Phase 2 CLN‑049 study in relapsed/refractory AML is expected to start in Q3 2026, alongside a planned AML combination trial in Q4 2026. Zipalertinib’s NDA for EGFR ex20ins NSCLC has a PDUFA date of February 27, 2027, with Cullinan eligible for up to $130 million in U.S. approval milestones and a 50/50 U.S. profit share.
Financially, cash and investments were $356 million as of June 30, 2026, which management expects to fund operations into 2029. Q2 2026 research and development expenses were $44.4 million and general and administrative expenses were $12.8 million, leading to a net loss of $53.7 million, compared with $70.1 million a year earlier.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an exercise-and-sell transaction in company stock. She sold 8,000 shares of common stock in an open-market sale at a weighted average price of $17.82 per share, executed under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2025. On the same date, she exercised stock options for 4,000 shares of common stock at an exercise price of $4.30 per share. After these transactions, she directly owned 162,844 shares of Cullinan Therapeutics common stock and held 112,987 stock options exercisable at $4.30 per share, which expire on October 28, 2030.
Company CGEM: proposed resale notice under Section 144. The filing lists proposed sales of 8,000 shares of Common Stock tied to insider-related sources. The listing shows 4,000 shares from exercise of stock options dated 07/06/2026 and 4,000 shares from Restricted Stock Units dated 02/22/2024. The excerpt also records prior 10b5-1 sales of 8,000 shares on 05/05/2026 for $116,976.02. The filing names a broker and provides an address for the selling party.
Cullinan Therapeutics Chief Legal Officer Jacquelyn L. Sumer acquired 2,470 shares of common stock at $8.60 per share through the company’s 2021 Employee Stock Purchase Plan. The shares relate to the purchase period from January 1, 2026 through June 30, 2026 and were bought at 85% of the January 2, 2026 closing price. Following this routine ESPP transaction, she directly holds 130,559 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics Chief Financial Officer Mary Kay Fenton reported an acquisition of company stock through the 2021 Employee Stock Purchase Plan. She obtained 1,541 shares of common stock for the purchase period from January 1, 2026 through June 30, 2026.
The shares were bought at $8.60 per share, based on 85% of the closing price on January 2, 2026, as provided under the ESPP. Following this routine, compensation-related transaction, she directly holds 127,921 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics director Anthony Rosenberg received a grant of stock options covering 25,319 shares of Common Stock. The options have an exercise price of $13.55 per share and will vest in full on the earlier of June 16, 2027 or the company’s next annual meeting, contingent on his continued board service. Following this compensation grant, he holds options for 25,319 underlying shares directly, with no open-market buying or selling reported in this filing.
Cullinan Therapeutics director David D. Meek received a new stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and represents a right to buy the company’s common stock directly.
According to the grant terms, the 25,319-share option will vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting, provided Meek continues to serve as a director through that vesting date. Following this grant, he holds stock options for 25,319 shares.
Cullinan Therapeutics director Stephen W. Webster received a stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and was awarded as compensation, not an open-market purchase or sale. It vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, contingent on his continued board service. Following this grant, Webster holds options for 25,319 underlying shares.